Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Another experimental therapy from Eli Lilly also helped patients shed pounds with few side effects in a small study, impressing analysts. The drug, called eloralintide, is part of a class of drugs ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

The stock of Eli Lilly has a consensus Strong Buy rating among 19 Wall Street analysts. That rating is based on 16 Buy, two ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses ...

How Eli Lilly Is Thinning Out the Competition. By Natalie Forbes – Aug 17, 2022 at 10:00AM Key Points. Latest earnings ... More potential in weight loss ...

Lilly’s stock soared after the company announced a successful trial of its new weight loss drug. Google Market These medications mimic a hormone called glucagon-like peptide-1, which regulates ...

FDA approves weight loss drug Zepbound, joining Ozempic and Wegovy in market 04:47. Eli Lilly has a message for people who are taking prescription medications developed for patients with Type 2 ...

In a groundbreaking move, Eli Lilly LLY is set to test its weight-loss medications on individuals who are not overweight but are at risk of gaining weight. What Happened: Dave Ricks, CEO of Eli ...

An experimental drug from Eli Lilly helped patients with obesity lose an average of 24% of their body weight over 48 weeks on the highest dose in a mid-stage study, the most weight loss seen yet ...

Eli Lilly's weighted average cost of capital is 7.08%, with an equity weight of 96.35% and a debt weight of 3.65%. Equity costs 7.27% and debt costs 2.64% after tax.

Eli Lilly (LLY 2.32%) is a leader in one of the pharmaceutical industry's highest-growth markets: weight loss drugs. This market may increase by 16x from today's size to reach $100 billion by the ...